Effect of thymidylate synthase gene polymorphism on the response to chemotherapy and clinical outcome of non-small cell lung cancer patients

Tumor Biology

Volumn 36, Issue 9, 2015, Pages 7151-7157

  Dong, Honglin ^a   Bao, Dengke ^b,c   Guo, Xu ^b   Hu, Jie ^a   Li, Xiaofei ^d   Wan, Shaogui ^c   Xing, Jinliang ^b  

^a SHANXI MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c HENAN UNIVERSITY   (China)

^d FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Non small cell lung cancer; Prognosis; Single nucleotide polymorphisms; Thymidylate synthase

Indexed keywords

BIOLOGICAL MARKER; THYMIDYLATE SYNTHASE; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENETIC MODEL; GENOTYPE; GENOTYPING TECHNIQUE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE FREE SURVIVAL; GENETIC ASSOCIATION; GENETICS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; TREATMENT OUTCOME; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; GENETIC ASSOCIATION STUDIES; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POLYMORPHISM, SINGLE NUCLEOTIDE; PRECISION MEDICINE; PROGNOSIS; THYMIDYLATE SYNTHASE; TREATMENT OUTCOME;

EID: 84947126813     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3447-6     Document Type: Article

References (34)

1. Cox G, Jones JL, Andi A, Waller DA, O’Byrne KJ. A biological staging model for operable non-small cell lung cancer. Thorax. 2001;56(7):561–6.
2. Grondin SC, Liptay MJ. Current concepts in the staging of non-small cell lung cancer. Surg Oncol. 2002;11(4):181–90.
3. Brambilla E, Travis WD, Colby TV, Corrin B, Shimosato Y. The new World Health Organization classification of lung tumours. Eur Respir J. 2001;18(6):1059–68.
4. Wakelee H, Belani CP. Optimizing first-line treatment options for patients with advanced NSCLC. Oncologist. 2005;10 Suppl 3:1–10. doi:10.1634/theoncologist.10-90003-1.
5. Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer. 2005;5(11):845–56. doi:10.1038/nrc1739.
6. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346(2):92–8. doi:10.1056/NEJMoa011954.
7. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(21):3543–51. doi:10.1200/JCO.2007.15.0375.
8. Tahara E, Yasui W, Ito H, Harris CC. Recent progress in carcinogenesis, progression and therapy of lung cancer: the 19th Hiroshima Cancer Seminar: the 3rd Three Universities’ Consortium International Symposium, November 2009. Jpn J Clin Oncol. 2010;40(7):702–8. doi:10.1093/jjco/hyq031.
9. Wu MF, Hsiao YM, Huang CF, Huang YH, Yang WJ, Chan HW, et al. Genetic determinants of pemetrexed responsiveness and nonresponsiveness in non-small cell lung cancer cells. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2010;5(8):1143–51. doi:10.1097/JTO.0b013e3181e0b954.
10. Johnston PG, Drake JC, Trepel J, Allegra CJ. Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines. Cancer Res. 1992;52(16):4306–12.
11. Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, Allegra CJ, Danenberg PV, et al. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res. 1995;55(7):1407–12.
12. Igawa S, Ryuge S, Wada M, Otani S, Maki S, Takakura A, et al. Pemetrexed for previously treated patients with non-small cell lung cancer and differences in efficacy according to thymidylate synthase expression. Chemotherapy. 2012;58(4):313–20. doi:10.1159/000343048.
13. Chen CY, Chang YL, Shih JY, Lin JW, Chen KY, Yang CH, et al. Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed. Lung Cancer. 2011;74(1):132–8. doi:10.1016/j.lungcan.2011.01.024.
14. Wang X, Wang Y, Cheng J, Ha M. Association of thymidylate synthase gene 3’-untranslated region polymorphism with sensitivity of non-small cell lung cancer to pemetrexed treatment: TS gene polymorphism and pemetrexed sensitivity in NSCLC. J Biomed Sci. 2013;20:5. doi:10.1186/1423-0127-20-5.
15. Xu J, Tian S, Yin Z, Wu S, Liu L, Qian Y, et al. MicroRNA-binding site SNPs in deregulated genes are associated with clinical outcome of non-small cell lung cancer. Lung Cancer. 2014;85(3):442–8. doi:10.1016/j.lungcan.2014.06.010.
16. Zhao HY, Ma GW, Zou BY, Li M, Lin SX, Zhao LP, et al. Prognostic significance of thymidylate synthase in postoperative non-small cell lung cancer patients. OncoTargets Ther. 2014;7:1301–10. doi:10.2147/OTT.S65067.
17. Tanaka F, Wada H, Fukui Y, Fukushima M. Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population. Ann Oncol Off J Eur Soc Med Oncol / ESMO. 2011;22(8):1791–7. doi:10.1093/annonc/mdq730.
18. Arevalo E, Castanon E, Lopez I, Salgado J, Collado V, Santisteban M, et al. Thymidylate synthase polymorphisms in genomic DNA as clinical outcome predictors in a European population of advanced non-small cell lung cancer patients receiving pemetrexed. J Transl Med. 2014;12:98. doi:10.1186/1479-5876-12-98.
19. Liu HB, Peng YP, Dou CW, Su XL, Gao NK, Tian FM, et al. Comprehensive study on associations between nine SNPs and glioma risk. Asian Pac J Cancer Prev: APJCP. 2012;13(10):4905–8.
20. Laing RE, Hess P, Shen Y, Wang J, Hu SX. The role and impact of SNPs in pharmacogenomics and personalized medicine. Curr Drug Metab. 2011;12(5):460–86.
21. Vesell ES. Advances in pharmacogenetics and pharmacogenomics. J Clin Pharmacol. 2000;40(9):930–8.
22. Chamary JV, Parmley JL, Hurst LD. Hearing silence: non-neutral evolution at synonymous sites in mammals. Nat Rev Genet. 2006;7(2):98–108. doi:10.1038/nrg1770.
23. Shen R, Liu H, Wen J, Liu Z, Wang LE, Wang Q, et al. Genetic polymorphisms in the microRNA binding-sites of the thymidylate synthase gene predict risk and survival in gastric cancer. Mol Carcinog. 2014. doi:10.1002/mc.22160.
24. Ho V, Massey TE, King WD. Thymidylate synthase gene polymorphisms and markers of DNA methylation capacity. Mol Genet Metab. 2011;102(4):481–7. doi:10.1016/j.ymgme.2010.12.015.
25. Xing J, Myers RE, He X, Qu F, Zhou F, Ma X, et al. GWAS-identified colorectal cancer susceptibility locus associates with disease prognosis. Eur J Cancer. 2011;47(11):1699–707. doi:10.1016/j.ejca.2011.02.004.
26. Zhou F, He X, Liu H, Zhu Y, Jin T, Chen C, et al. Functional polymorphisms of circadian positive feedback regulation genes and clinical outcome of Chinese patients with resected colorectal cancer. Cancer. 2012;118(4):937–46. doi:10.1002/cncr.26348.
27. Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006;355(10):983–91. doi:10.1056/NEJMoa060570.
28. Zheng Z, Chen T, Li X, Haura E, Sharma A, Bepler G. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med. 2007;356(8):800–8. doi:10.1056/NEJMoa065411.
29. Sharp L, Little J. Polymorphisms in genes involved in folate metabolism and colorectal neoplasia: a HuGE review. Am J Epidemiol. 2004;159(5):423–43.
30. Shintani Y, Ohta M, Hirabayashi H, Tanaka H, Iuchi K, Nakagawa K, et al. New prognostic indicator for non-small-cell lung cancer, quantitation of thymidylate synthase by real-time reverse transcription polymerase chain reaction. Int J Cancer J Int Cancer. 2003;104(6):790–5. doi:10.1002/ijc.11014.
31. Grimminger PP, Schneider PM, Metzger R, Vallbohmer D, Holscher AH, Danenberg PV, et al. Low thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase mRNA expression correlate with prolonged survival in resected non-small-cell lung cancer. Clin Lung Cancer. 2010;11(5):328–34. doi:10.3816/CLC.2010.n.041.
32. Miyoshi T, Kondo K, Toba H, Yoshida M, Fujino H, Kenzaki K, et al. Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (tegafur+uracil) in patients with non-small cell lung cancer. Anticancer Res. 2007;27(4C):2641–8.
33. Shimizu T, Nakanishi Y, Nakagawa Y, Tsujino I, Takahashi N, Nemoto N, et al. Association between expression of thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase and efficacy of pemetrexed in advanced non-small cell lung cancer. Anticancer Res. 2012;32(10):4589–96.
34. Peters EJ, Kraja AT, Lin SJ, Yen-Revollo JL, Marsh S, Province MA, et al. Association of thymidylate synthase variants with 5-fluorouracil cytotoxicity. Pharmacogenet Genomics. 2009;19(5):399–401. doi:10.1097/FPC.0b013e328329fdec.